VivoSeq
Other

Dexmedetomidine

5

Pipeline Programs

77

Active Trials

6

Companies Involved

Dexmedetomidine is an early-stage landscape with 5 programs across 6 companies. The most active players are Dr. Naveed Siddiqui, Cloudbreak Therapeutics, LLC, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 2 therapies are approved.

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

58/100

Mech. Concentration

33/100

Completion Rate

90/100

Attrition Rate

6/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

423

clinical trials

Completed237 · 56%
Unknown status84 · 20%
Recruiting42 · 10%
Not yet recruiting28 · 7%
Withdrawn16 · 4%
Terminated8 · 2%
Other8 · 2%

Trial Activity

423 trials

Dexmedetomidine vs Midazolam in Coronary Artery By-pass Surgery
Recruiting··N/A·NCT07411794·60 enrolled
Page 1 of 29

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)